Remove Access Remove Clinical Trials Remove DEA
article thumbnail

NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules

NORML

Under existing regulations, the agency only licenses one facility — the University of Mississippi — to cultivate cannabis for use in FDA-approved clinical trials. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received.

article thumbnail

ASA offers solution to DOJ research block: Our comments on the DEA’s proposed rules

Americans for Safe Access

On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

House Passes Bipartisan Bill Facilitating Clinical Cannabis Research, Allowing Scientists to Access State-Approved Marijuana Products

NORML

The reality that most high-schoolers have easier access to cannabis than do our nation’s top scientists is the height of absurdity and an indictment of the current system.”. “These common-sense regulatory changes are necessary and long overdue.

Access 246
article thumbnail

Physician Sues The DEA For Access To Psilocybin For The Terminally Ill With Ample Support From Experts And Institutions

Cannabis Law Report

A Seattle palliative care physician has filed a lawsuit against the DEA, contesting its decision to ban psilocybin for use by terminally ill patients. Background of the Case. Read more .

DEA 98
article thumbnail

Justice Department Urged To Take “Immediate Action” On Marijuana Grow Applications

NORML

” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue.

DEA 182
article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.

DEA 104
article thumbnail

NORML “Senate Unanimously Approves Legislation Providing US Attorney General with Greater Say in Cannabis Research Decisions”

Cannabis Law Report

Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. The full text of S. 253 is online here.